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E SYNTHASE-1 EXPRESSION IN HUMAN CHONDROCYTES:
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J.-P. Pelletier, H. Fahmi
Montreal Univ., Montreal, QC, Canada
Purpose: Microsomal prostaglandin E synthase-1 (mPGES-1), an
inducible enzyme, catalyzes the terminal step in the biosynthesis
of PGE2, which plays a critical role in the pathogenesis of os-
teoarthritis (OA). mPGES-1 is strongly induced by inﬂammatory
cytokines and is upregulated in OA cartilage. Egr-1 is a key tran-
scription factor in inducible mPGES-1 expression. In the present
study, we examined the effect of three histone deacetylase (HDAC)
inhibitors, trichostatin A (TSA), valproic acid (VA), and butyric acid
(BA) on IL-1-induced mPGES-1 expression, Egr-1 expression and
Egr-1 DNA-binding activity in human OA chondrocytes.
Methods: Chondrocytes were stimulated with IL-1 in the ab-
sence or presence of increasing concentrations of TSA, VA or
BA. The expression of mPGES-1 and Egr-1 proteins and mR-
NAs was evaluated using Western blotting and real-time reverse
transcriptase-polymerase chain reaction (RT-PCR), respectively.
Electrophoretic mobility shift assay (EMSA) was utilized to analyze
the DNA-binding activity of Egr-1 in vitro, and Chromatin Immuno-
precipitation (ChIP) was used to evaluate the recruitment of Egr-1
to the mPGES-1 promoter in vivo.
Results: Treatment with each of the HDAC inhibitors (TSA, VA
and BA) reduced IL-1-induced mPGES-1 protein expression in
a dose-dependent manner. The induction of mPGES-1 mRNA
expression was also dose-dependently inhibited. Treatment with
HDAC inhibitors did not alter IL-1-induced Egr-1 expression. Fi-
nally, we demonstrate that the HDAC inhibitors did not affect the
DNA-binding activity of Egr-1 nor its binding to the endogenous
mPGES-1 promoter.
Conclusions: These data indicate that HDAC inhibitors sup-
presse IL-1-induced mPGES-1 expression. The suppressive effect
of HDAC inhibitors is not due to impaired expression of Egr-1 nor
to its DNA-binding activity. These ﬁndings also suggest that HDAC
inhibitors may be of potential therapeutic value in the treatment of
OA.
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ASSOCIATION OF LEPTIN GENE (LEP) WITH KNEE
OSTEOARTHRITIS SUSCEPTIBILITY IN HAN CHINESE
Q. Jiang, J. Qin, J. Dai, L. Zhu, D. Shi
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Purpose: Former studies suggested that leptin worked as a key
regulator in the pathogenesis of osteoarthritis (OA). This study
assessed the contribution of leptin gene polymorphism to knee
OA in Chinese Han population.
Methods: 3 tag SNPs of LEP were selected by haploviewer soft-
ware from Hapmap database. They cover all the SNPs of LEP
whose heterozygosis rate are over 10%. We genotyped the se-
lected SNPs in 719 patients who had symptomatic knee OA with
radiographic conﬁrmation and 699 age matched controls, com-
pared allelic and genotypic frequencies and haplotype distribution.
Results: Statistical difference was observed in body mass index
(BMI) (P<0.0001) but not in age between case and control groups
in Chinese Han populations (P=0.257). After stratiﬁcation by gen-
der, associations were observed with allele frequency (T vs. C,
P=0.037) and genotype (CC vs. others, P=0.046) in rs2071045,
and haplotype AGT shows a signiﬁcant difference (P=0.010) in fe-
male. No signiﬁcant difference was detected in male (all P>0.05).
Furthermore, no association between the genotypes and the clin-
ical variables, age, sex, BMI and Kellgren/Lawrence score was
observed in OA patients.
Conclusions: These ﬁndings suggest there is an association
between LEP and knee OA in female Han Chinese. It’s a ﬁrst
report examined the relationship between LEP polymorphisms
and the knee OA.
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Purpose: Cytosolic group IVA phospholipase A2 (cPLA2α), en-
coded by PLA2G4A, catalyzes the rate-limiting step in the pro-
duction of pro-inﬂammatory eicosanoids and free radicals. This
enzyme is involved in receptor-activated signalling cascades, in
particular MAPK/p38 and has been shown to play pivotal roles
in several physiological processes. We hypothesized that vari-
ation in this gene could affect susceptibility to systemic lupus
erythematosus (SLE), a systemic autoimmune and inﬂammatory
disease characterized by autoantibody production and involvement
of multiple organ systems and a variety of symptoms, including
arthropathy. Variants near the PLA2G4A gene have also been
implicated in risk of osteoarthritis (OA), the most common form of
arthritis in the elderly. We assessed the role of genetic variation in
the PLA2G4A gene in susceptibility to SLE, knee OA and hip OA
Methods: We genotyped 18 variants in the PLA2G4A gene and
identiﬁed 3 markers signiﬁcantly associated with SLE in 1781
cases and 2254 controls from Argentina, Belgium, Germany, Hun-
gary, Italy, Portugal, Spain and Sweden. The four PLA2G4A mark-
ers showing the strongest association with SLE were subsequently
typed in 2190 OA cases and 1535 controls from the UK
Results: Three markers in the PLA2G4A were found to be nomi-
nally signiﬁcantly associated (p<0.05) with SLE. All three of them
and an additional marker with p<0.20 with SLE were typed in OA
samples and were found to be signiﬁcantly associated with risk of
knee OA. Two of the markers were also signiﬁcantly associated
with risk of total hip replacement. Overall the strongest association
with SLE was seen at rs17591814 (ORSLE = 0.87 95%CI 0.79-0.95
p<0.0078 ORkneeOA = 0.87 95%CI 0.77-0.98 p<0.025; ORhip OA =
0.95 95% CI 0.83-1.09 n.s.) and the strongest association with OA
was seen at rs726706 (ORSLE = 0.90 95%CI 0.81-0.98 p<0.034
ORkneeOA = 0.82 95%CI 0.73-0.91 p<2.4×10-4; ORhip OA = 0.82
95%CI 0.72-0.93 p<0.0016).
Conclusions: Our data indicate that genetic variation in this key
enzyme regulating immunoinﬂammatory reactions is involved in
susceptibility to both SLE and OA, in spite of the fact that these
arthropathies have extremely different manifestations.This work
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